Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 387

1.

Psoriasis, psoriatic arthritis, and rheumatoid arthritis: Is all inflammation the same?

Coates LC, FitzGerald O, Helliwell PS, Paul C.

Semin Arthritis Rheum. 2016 Jun 2. pii: S0049-0172(16)30064-6. doi: 10.1016/j.semarthrit.2016.05.012. [Epub ahead of print] Review.

2.

Spondyloarthropathies: IL-6 blockade in psoriatic arthritis - a new therapeutic option?

FitzGerald O.

Nat Rev Rheumatol. 2016 May 24;12(6):318-9. doi: 10.1038/nrrheum.2016.84. No abstract available.

PMID:
27215204
3.

GRAPPA 2015 Research and Education Project Reports.

Mease PJ, Helliwell PS, Boehncke WH, Coates LC, FitzGerald O, Gladman DD, Deodhar AA, Callis Duffin K.

J Rheumatol. 2016 May;43(5):979-85. doi: 10.3899/jrheum.160119.

PMID:
27134274
4.

Report of the GRAPPA-OMERACT Psoriatic Arthritis Working Group from the GRAPPA 2015 Annual Meeting.

Orbai AM, Mease PJ, de Wit M, Kalyoncu U, Campbell W, Tillett W, Eder L, Elmamoun M, FitzGerald O, Gladman DD, Goel N, Gossec L, Lindsay CA, Steinkoenig I, Helliwell PS, McHugh NJ, Strand V, Ogdie A.

J Rheumatol. 2016 May;43(5):965-9. doi: 10.3899/jrheum.160116.

5.

Replication of a distinct psoriatic arthritis risk variant at the IL23R locus.

Budu-Aggrey A, Bowes J, Loehr S, Uebe S, Zervou MI, Helliwell P, Ryan AW, Kane D, Korendowych E, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Behrens F, Burkhardt H, Huffmeier U, Ho P, Martin J, Castañeda S, Goulielmos G, Reis A, Barton A.

Ann Rheum Dis. 2016 Jul;75(7):1417-8. doi: 10.1136/annrheumdis-2016-209290. Epub 2016 Mar 25. No abstract available.

6.

Perceptions of the Cause, Impact and Management of Persistent Fatigue in Patients with Rheumatoid Arthritis Following Tumour Necrosing Factor Inhibition Therapy.

Minnock P, Ringnér A, Bresnihan B, Veale D, FitzGerald O, McKee G.

Musculoskeletal Care. 2016 Feb 12. doi: 10.1002/msc.1136. [Epub ahead of print]

PMID:
26871999
7.

Predictive validity of the ASAS classification criteria for axial and peripheral spondyloarthritis after follow-up in the ASAS cohort: a final analysis.

Sepriano A, Landewé R, van der Heijde D, Sieper J, Akkoc N, Brandt J, Braun J, Collantes-Estevez E, Dougados M, Fitzgerald O, Huang F, Gu J, Kirazli Y, Maksymowych WP, Marzo-Ortega H, Olivieri I, Ozgocmen S, Roussou E, Scarpato S, Sørensen IJ, Valle-Oñate R, Van den Bosch F, van der Horst-Bruinsma I, Weber U, Wei J, Rudwaleit M; ASAS.

Ann Rheum Dis. 2016 Jun;75(6):1034-42. doi: 10.1136/annrheumdis-2015-208730. Epub 2016 Feb 10.

PMID:
26865599
8.

Striking difference of periarticular bone density change in early psoriatic arthritis and rheumatoid arthritis following anti-rheumatic treatment as measured by digital X-ray radiogrammetry.

Szentpetery A, Heffernan E, Haroon M, Kilbane M, Gallagher P, McKenna MJ, FitzGerald O.

Rheumatology (Oxford). 2016 May;55(5):891-6. doi: 10.1093/rheumatology/kev443. Epub 2016 Feb 4.

9.

Higher Prevalence of Metabolic Syndrome in Patients with Psoriatic Arthritis: A Comparison with a Control Group of Noninflammatory Rheumatologic Conditions.

Haroon M, Rafiq Chaudhry AB, Fitzgerald O.

J Rheumatol. 2016 Feb;43(2):463-4. doi: 10.3899/jrheum.150757. No abstract available.

PMID:
26834258
10.

Improving recognition of spondyloarthropathy in primary care: an unmet need.

Haroon M, FitzGerald O.

Ann Rheum Dis. 2016 Apr;75(4):e19. doi: 10.1136/annrheumdis-2016-209118. Epub 2016 Jan 28. No abstract available.

PMID:
26823529
11.

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis.

Coates LC, Kavanaugh A, Mease PJ, Soriano ER, Laura Acosta-Felquer M, Armstrong AW, Bautista-Molano W, Boehncke WH, Campbell W, Cauli A, Espinoza LR, FitzGerald O, Gladman DD, Gottlieb A, Helliwell PS, Husni ME, Love TJ, Lubrano E, McHugh N, Nash P, Ogdie A, Orbai AM, Parkinson A, O'Sullivan D, Rosen CF, Schwartzman S, Siegel EL, Toloza S, Tuong W, Ritchlin CT.

Arthritis Rheumatol. 2016 May;68(5):1060-71. doi: 10.1002/art.39573. Epub 2016 Mar 23.

PMID:
26749174
12.

Psoriatic arthritis: complexities, comorbidities and implications for the clinic.

Haroon M, FitzGerald O.

Expert Rev Clin Immunol. 2016 Apr;12(4):405-16. doi: 10.1586/1744666X.2016.1139453. Epub 2016 Jan 28.

PMID:
26735626
13.

European League Against Rheumatism (EULAR) recommendations for the management of psoriatic arthritis with pharmacological therapies: 2015 update.

Gossec L, Smolen JS, Ramiro S, de Wit M, Cutolo M, Dougados M, Emery P, Landewé R, Oliver S, Aletaha D, Betteridge N, Braun J, Burmester G, Cañete JD, Damjanov N, FitzGerald O, Haglund E, Helliwell P, Kvien TK, Lories R, Luger T, Maccarone M, Marzo-Ortega H, McGonagle D, McInnes IB, Olivieri I, Pavelka K, Schett G, Sieper J, van den Bosch F, Veale DJ, Wollenhaupt J, Zink A, van der Heijde D.

Ann Rheum Dis. 2016 Mar;75(3):499-510. doi: 10.1136/annrheumdis-2015-208337. Epub 2015 Dec 7.

PMID:
26644232
14.

Effect of certolizumab pegol over 96 weeks in patients with psoriatic arthritis with and without prior antitumour necrosis factor exposure.

Mease P, Deodhar A, Fleischmann R, Wollenhaupt J, Gladman D, Leszczyński P, Vitek P, Turkiewicz A, Khraishi M, FitzGerald O, Landewé R, de Longueville M, Hoepken B, Peterson L, van der Heijde D.

RMD Open. 2015 Jun 25;1(1):e000119. doi: 10.1136/rmdopen-2015-000119. eCollection 2015.

15.

Peripheral joint involvement in psoriatic arthritis patients.

Acosta Felquer ML, FitzGerald O.

Clin Exp Rheumatol. 2015 Sep-Oct;33(5 Suppl 93):S26-30. Epub 2015 Oct 15. Review.

PMID:
26471860
16.

Factors that influence fatigue status in patients with severe rheumatoid arthritis (RA) and good disease outcome following 6 months of TNF inhibitor therapy: a comparative analysis.

Minnock P, Veale DJ, Bresnihan B, FitzGerald O, McKee G.

Clin Rheumatol. 2015 Nov;34(11):1857-65. doi: 10.1007/s10067-015-3088-6. Epub 2015 Oct 9.

17.

Guideline Promotion Increases Prescription of Bone Protection with Steroids in Hospitalised Patients.

Harty L, Clare J, Finnerty D, van der Kamp S, Kennedy F, Callanan I, McKenna MJ, FitzGerald O.

Ir Med J. 2015 Jul-Aug;108(7):216-7.

PMID:
26349354
18.

Developing clinically relevant biomarkers in inflammatory arthritis: A multiplatform approach for serum candidate protein discovery.

McArdle A, Qasim Butt A, Szentpetery A, de Jager W, de Roock S, FitzGerald O, Pennington SR.

Proteomics Clin Appl. 2016 Jun;10(6):691-8. doi: 10.1002/prca.201500046. Epub 2015 Nov 9.

PMID:
26332844
19.

Corrigendum: Dense genotyping of immune-related susceptibility loci reveals new insights into the genetics of psoriatic arthritis.

Bowes J, Budu-Aggrey A, Huffmeier U, Uebe S, Steel K, Hebert HL, Wallace C, Massey J, Bruce IN, Bluett J, Feletar M, Morgan AW, Marzo-Ortega H, Donohoe G, Morris DW, Helliwell P, Ryan AW, Kane D, Warren RB, Korendowych E, Alenius GM, Giardina E, Packham J, McManus R, FitzGerald O, McHugh N, Brown MA, Ho P, Behrens F, Burkhardt H, Reis A, Barton A.

Nat Commun. 2015 Jul 6;6:7741. doi: 10.1038/ncomms8741. No abstract available.

PMID:
26145464
20.

A clinically based protein discovery strategy to identify potential biomarkers of response to anti-TNF-α treatment of psoriatic arthritis.

Collins ES, Butt AQ, Gibson DS, Dunn MJ, Fearon U, van Kuijk AW, Gerlag DM, Pontifex E, Veale DJ, Tak PP, FitzGerald O, Pennington SR.

Proteomics Clin Appl. 2016 Jun;10(6):645-62. doi: 10.1002/prca.201500051. Epub 2015 Sep 28.

PMID:
26108918
Items per page

Supplemental Content

Loading ...
Write to the Help Desk